(VIANEWS) – Shares of BENEVOLENTAI (AEX-Index: BAI.AS) slid by a staggering 16.39% in 5 sessions from €2.38 to €1.99 at 02:08 EST on Monday, after five successive sessions in a row of losses. AEX-Index is jumping 0.14% to €762.19, after two sequential sessions in a row of gains.
BENEVOLENTAI’s last close was €1.99, 80.1% below its 52-week high of €10.00.
About BENEVOLENTAI
BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
Earnings Per Share
As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-1.55.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -151.13%.
Volatility
BENEVOLENTAI’s last week, last month’s, and last quarter’s current intraday variation average was a negative 6.17%, a negative 1.35%, and a positive 4.29%.
BENEVOLENTAI’s highest amplitude of average volatility was 6.17% (last week), 4.38% (last month), and 4.29% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 93.1%, now sitting on 10.56M for the twelve trailing months.
Moving Average
BENEVOLENTAI’s worth is way below its 50-day moving average of €3.11 and way below its 200-day moving average of €4.48.
Volume
Today’s last reported volume for BENEVOLENTAI is 70 which is 94.49% below its average volume of 1816.
More news about BENEVOLENTAI (BAI.AS).
